We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.4B
AUM Growth
-$764M
Cap. Flow
-$999M
Cap. Flow %
-41.57%
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$94.4M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$24M
3
AGN
Allergan plc
AGN
+$13.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$11.9M
5
MBLY
Mobileye N.V.
MBLY
+$8.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$42.1M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$27.4M
3
AZN icon
AstraZeneca
AZN
+$13.5M
4
GILD icon
Gilead Sciences
GILD
+$11.5M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.1M

Sector Composition

Rank Sector Weight
1 Miscellaneous 88.65%
2 Healthcare 9.88%
3 Technology 0.55%
4 Energy 0.39%
5 Industrials 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATHX
201
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$823K 0.03%
114
+50
+78% +$3.02K
TLPH icon
202
Talphera
TLPH
$62.8M
$806K 0.03%
+10,446
New +$1.37M
MDGL icon
203
Madrigal Pharmaceuticals
MDGL
$12B
$794K 0.03%
+11,400
New +$978K
CLLS
204
Cellectis
CLLS
$167M
$785K 0.03%
+22,700
New +$824K
BIOL
205
DELISTED
Biolase, Inc.
BIOL
$760K 0.03%
+30
New +$850K
DYAX
206
PUT
DELISTED
DYAX CORPORATION
DYAX
$757K 0.03%
+452
New +$7.04K
RCPT
207
PUT
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$742K 0.03%
+45
New +$5.69K
NURO
208
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$699K 0.03%
161
+19
+13% +$83.7K
CBAY
209
DELISTED
Cymabay Therapeutics
CBAY
$692K 0.03%
100,000
-800
-0.8% -$7.68K
CASC
210
DELISTED
Cascadian Therapeutics, Inc.
CASC
$681K 0.03%
69,659
-51,091
-42% -$501K
INSM icon
211
CALL
Insmed
INSM
$26.2B
$678K 0.03%
326
+30
+10% +$529
ACGN
212
PUT
DELISTED
Aceragen Inc
ACGN
$675K 0.03%
+2
New +$9.76K
VIRX
213
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$673K 0.03%
+1,309
New +$660K
ALKS icon
214
CALL
Alkermes
ALKS
$7.58B
$622K 0.03%
102
+48
+89% +$3.28K
IMNN icon
215
Imunon
IMNN
$8.14M
$616K 0.03%
84
-82
-49% -$570K
NUVA
216
CALL
DELISTED
NuVasive, Inc.
NUVA
$616K 0.03%
+134
New +$6.22K
MDCO
217
CALL
DELISTED
Medicines Co
MDCO
$611K 0.03%
+218
New +$6.12K
CTIC
218
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$600K 0.03%
33,163
+8,663
+35% +$195K
AGIO icon
219
PUT
Agios Pharmaceuticals
AGIO
$1.94B
$585K 0.02%
62
+30
+94% +$3.36K
TLPH icon
220
CALL
Talphera
TLPH
$62.8M
$585K 0.02%
+76
New +$9.94K
KITE
221
PUT
DELISTED
Kite Pharma, Inc.
KITE
$565K 0.02%
+98
New +$6.57K
MBLY
222
CALL
DELISTED
Mobileye N.V.
MBLY
$551K 0.02%
131
-77
-37% -$3K
LITS
223
Lite Strategy Inc
LITS
$37.4M
$531K 0.02%
14,825
-15,175
-51% -$1.36M
IMMU
224
DELISTED
Immunomedics Inc
IMMU
$528K 0.02%
+137,751
New +$599K
GEVA
225
PUT
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$527K 0.02%
+54
New +$5.72K
7 8
9
10 11

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sabby Management held 367 positions worth $2.4B, down 24% from $3.17B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management withdrew a net $999M in Q1 2015, closing 85 positions and reducing 66 holdings. Its most notable exit was Pfizer, an estimated $42.1M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, down from 90% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Sabby Management opened a new position in Tempest Therapeutics worth $4.69M.

  • Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
  • Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
  • Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
  • Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
  • Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
  • Sabby Management opened 126 new positions and closed 85 in Q1 2015.
  • Sabby Management's portfolio value fell 24% quarter-over-quarter to $2.4B.

Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.